Life Insurance Regulations 2024

The instrument introduces and fixes a concise set of concepts used to operationalise the Act. Each prescribed concept is tied to a particular provision or purpose in the Act (the instrument repeatedly uses the phrase "For the purposes of..." when linking to Act provisions).

Key defined concepts and mechanics:

• Allocated annuity policy: a life policy providing an annuity paid within a specified range from an identifiable lump sum, or a contract that meets standards of subregulation 1.05(4) of the Superannuation Industry (Supervision) Regulations 1994 (s 4). This cross‑references the SIS Regulations; the instrument makes the cross‑reference operative for the Act by definition.
• Deferred annuity policy and immediate annuity policy: defined by reference to whether the annuity is presently payable (s 4).
• Minimum term of annuity: for paragraph 9(1)(d) of the Act the prescribed term is 10 years (s 5). The instrument thus gives a concrete temporal threshold where the Act refers to "term".
• Eligible foreign life insurance company: the instrument identifies five jurisdictions (China, Japan, New Zealand, Republic of Korea, United States of America) and prescribes that the body corporate must both be incorporated in, and authorised to carry on life insurance business in, the relevant jurisdiction (s 6(1)). It explicitly excludes certain WTO members from a reference to China (Hong Kong, Macao, Separate Customs Territory of Taiwan, Penghu, Kinmen and Matsu) (s 6(2)).
• Transfer/amalgamation procedural concepts: an "approved summary of the scheme" must be given to every affected policy holder; an application for confirmation of the scheme to the Court must not be made earlier than 15 days after the first day that approved summary has been given (s 7(1)). The instrument lists precise documents that the latter company must give APRA when a life insurance business is transferred or amalgamated (s 8(1)), and prescribes timing (30 days), extension mechanics, and treatment of APRA's decision as a reviewable decision in certain circumstances (s 8(2)-(5)).
• Interest on overdue premiums: a concrete formula is prescribed , rate = (10 year Commonwealth Government bond yield) + 3 percentage points (s 9(1)). The "10 year Commonwealth Government bond yield" is defined as the mean of the 10 year yields shown in Reserve Bank of Australia figures at the ends of the last six successive half financial years ending before the day in question (s 9(2)), with rounding down to the nearest 0.25% (s 9(3)).
• Unclaimed money interest: defines the "interest period" (starts on later of 1 July 2013 or the day the life company paid the unclaimed money to Commonwealth; ends 14 days after Minister causes payment back to the life company) (s 10(5)); directs per‑financial‑year computations using CPI quarter changes (s 10(7)-(10)), with rounding protocols and the rule that negative calculated rates are floored to zero (s 10(11)).
• Net claim value of a policy: the net claim value equals the amount payable in respect of the claim less debts owed under or secured by the policy (s 11(2)). "Amount payable" is context‑sensitive (maturity/death or voluntary termination) (s 11(2)(a)-(b)).

Finally, Schedule 1 lists "approved bodies" , an extensive table of exchanges, clearing houses and similar entities, plus a catch‑all item for clearing houses that perform functions in relation to an approved body (Sch 1, item 167). The instrument also prescribes the meaning of "approved body" for Schedule 1 to the Act (s 14).

These concepts convert several abstract references in the Act into precise, operational items for use by life companies, APRA, courts and the Minister.

The instrument directly and immediately affects a narrow set of actors named and implied in its provisions. Who pays, who decides, and who must act are identifiable from the text.

Primary affected parties

• Life companies: the instrument repeatedly addresses life companies, for example by prescribing the documents a latter company must provide to APRA after a transfer or amalgamation (s 8(1)), prescribing interest they may charge on overdue premiums (s 9), instructing how to compute net claim values (s 11), and specifying how interest is to be calculated when unclaimed money is returned to them by the Commonwealth (s 10). Life companies are therefore the principal regulated entities.
• APRA (Australian Prudential Regulation Authority): APRA receives documents after transfers/amalgamations (s 8(1)-(2)), is empowered to grant or refuse short extensions to the documents deadline (s 8(3)-(4)), and must notify its decision in writing (s 8(4)(b)). The instrument prescribes APRA's procedural role.
• The Court: the Court is referenced as the body that confirms schemes under the Act. The instrument makes its application timing subject to the Court’s power to dispense with giving the approved summary (s 7(2)); also, a certified copy of the Court order confirming the scheme must be supplied to APRA (s 8(1)(b)(iv)).
• Affected policy holders: the timing rule for applications for confirmation of schemes is tied to the giving of an "approved summary" to every affected policy holder (s 7(1)). Policy holders receive the summary and thus acquire a temporal protection under the regulation in relation to the scheme confirmation process.
• The Minister (responsible for returning unclaimed money): s 10(5)(b) uses the phrase "the day on which the Minister causes the unclaimed money to be paid to the life company", which makes the Minister an actor determining when interest period ends for returned unclaimed money.
• Principal executive officer of the transferee (latter) company: s 8(1)(c) requires a statutory declaration by the principal executive officer about payments made and estimates of future payments in relation to the transfer/amalgamation, and a declaration that no other payments have been made or will be made in relation to the transfer or amalgamation by, or with the knowledge of, a party to the agreement or deed.
• Foreign life insurers and their Australian branches: s 6 prescribes which foreign life insurers qualify as "eligible" under paragraph 16ZD(1)(e) of the Act, by reference to incorporation and authorisation in the listed jurisdictions (China, Japan, New Zealand, Republic of Korea, United States of America). That directly affects foreign life insurers that wish to operate Australian branches under the Act’s special provisions.

Secondary and cross‑sector actors

• Entities involved in clearing and markets listed in Schedule 1: the long list of exchanges and clearing houses included as "approved bodies" will affect counterparties, clearing participants and possibly prudential treatment where the Act references "approved body" in its Schedule 1 definition.
• Persons authorised to certify copies under the Statutory Declarations Act 1959 for the purposes of a "certified copy of a document" used in s 8(1)(b) are implicated via the definition in s 4.

Overall, the instrument delineates duties and procedural timelines for life companies and APRA, conditions for foreign companies, computation rules affecting financial outcomes for policy holders and life companies, and administrative tasks affecting principals and the Minister.

The instrument prescribes specific duties, time limits and computational entitlements. It mostly fills out requirements that the Act references but leaves substantive enforcement to the Act itself. Below are the primary duties and rights created or clarified by the instrument, with statutory pointers.

Duties on life companies and transferee companies

• Provide documents to APRA after transfer or amalgamation: where any part of the life insurance business carried on by a life company is transferred to, or amalgamated with, another company, the latter company must give APRA (within the timelines discussed below) a statement of the nature and terms of the transfer or amalgamation, and certified copies of specified documents: the scheme, actuarial or other reports on which the scheme and agreement or deed are founded, the agreement or deed by which transfer/amalgamation is carried out, the Court order confirming the scheme, and a statement of assets and liabilities of each company affected by the scheme (s 8(1)(a)-(b)).
• Provide a statutory declaration by the principal executive officer: the latter company must supply a statutory declaration setting out all payments made in relation to the transfer or amalgamation, a reasonable estimate of future payments, and a statement that no other payments have been or will be made in relation to the transfer or amalgamation by, or with the knowledge of, a party to the agreement or deed (s 8(1)(c)(i)-(iii)).
• Timing for documents: the documents must be given to APRA within 30 days after completion of the transfer or amalgamation (s 8(2)). A company may apply to APRA for an extension before the 30 days expire (s 8(3)). The instrument prescribes APRA’s response timetable and range of discretion (s 8(4)).
• Application timing for confirmation of scheme: an application under paragraph 191(2)(e) of the Act must not be made earlier than 15 days after the first day on which an approved summary of the scheme has been given to every affected policy holder in accordance with paragraph 191(2)(c) of the Act (s 7(1)). That duty is subject to the Court’s power to dispense with the requirement (s 7(2)).

Duties and rights in financial calculations

• Interest rate on overdue premiums: the instrument prescribes that the rate of interest chargeable on an overdue premium on a day is the rate computed as 10 year Commonwealth Government bond yield plus 3 per cent, with the yield defined as a six‑point mean of published RBA yields at specified half‑financial year ends and with rounding down to the nearest 0.25% where necessary (s 9(1)-(3)). This gives life companies a specified permissible interest rate formula they may rely on under subsection 210(3) of the Act.
• Interest on returned unclaimed money: where the Commonwealth pays unclaimed money back to a life company, the instrument prescribes how to compute interest payable to the life company under paragraph 216(7A)(a) of the Act (s 10(2)). It prescribes the interest period (s 10(5)), a per‑financial‑year additive computation (s 10(6)-(7)), the CPI‑based method for calculating the interest rate for each financial year (s 10(9)), and rounding rules (s 10(8), (10)-(11)). Life companies and the Commonwealth therefore have a clear method for settling interest in those circumstances.
• Net claim value calculation: for the purposes of subsection 223(2) of the Act, the net claim value at a particular time is the amount payable in respect of the claim less debts owed to the life company under the policy or secured by the policy (s 11(2)). This is a duty to apply that arithmetic when calculating statutory net claim values.

APRA’s procedural duties and rights

• Consider and decide extension applications: if a company applies in writing to APRA for an extension of time before the end of the 30 days, APRA must, within 14 days after receiving the application, either (i) give an extension of time of no longer than 30 days if APRA believes it was not reasonably possible for the company to give the documents within 30 days; or (ii) refuse the application. APRA must give the company written notice of its decision (s 8(3)-(4)). The instrument prescribes a limited, reason‑gated discretion and a strict decision timetable.
• Reviewability of refusal: the instrument prescribes that a decision to refuse an application for an extension under s 8(4)(a)(ii) is a "reviewable decision" for the purposes of paragraph (zt)(ii) of the definition of reviewable decision in subsection 236(1) of the Act (s 8(5)). This gives companies a statutory pathway to challenge refusals under the Act’s review mechanisms.

Other rights and interactions

• Court dispensing power: s 7(2) preserves the Court’s power under subsection 191(5) of the Act to dispense with compliance with the requirement to give an approved summary, so applicants for confirmation of a scheme retain the right to seek judicial dispensation from the timing rule.
• Certified copies and certification: the instrument requires "certified copies" of documents; a certified copy is defined as a copy certified in writing by a person prescribed for purposes of paragraph 8(b) of the Statutory Declarations Act 1959 (s 4). This delegates the identity of suitable certifiers to the Statutory Declarations Act regime.

Collectively, these duties substitute precise procedural and arithmetic rules for otherwise open‑ended references in the Act, creating predictable obligations for life companies, procedural calendars for APRA and defined calculations for financial outcomes.

The instrument itself does not create a standalone civil or criminal penalty schedule. Instead, it prescribes procedural and substantive requirements "for the purposes of" particular sections of the Life Insurance Act 1995. Enforcement of compliance with these prescribed requirements therefore sits within the Act’s enforcement and regulatory framework rather than in the instrument. The instrument does, however, specify one explicit enforcement‑relevant mechanism and multiple procedural obligations whose non‑compliance will engage Act processes.

Reviewable decision and APRA’s refusal

• APRA refusal as reviewable decision: the instrument prescribes that a decision to refuse an application for an extension of time under s 8(4)(a)(ii) of the instrument is a "reviewable decision" for the purposes of paragraph (zt)(ii) of the definition of reviewable decision in subsection 236(1) of the Act (s 8(5)). That prescription means a company refused an extension may seek review under the Act’s review procedures enumerated in s 236 and related provisions. The Act, not the instrument, will determine the available review forum, time limits and remedies for review.
• APRA’s procedural obligation: APRA must decide within 14 days whether to grant or refuse an extension and must give written notice of its decision (s 8(4)(a)-(b)). The instrument therefore creates a statutory timetable for APRA that, if breached, could be the subject of review or complaint under the Act, subject to the Act’s remedies and processes.

Obligations that implicate Act enforcement

• Document supply and statutory declaration obligations: the requirement on the latter company to provide specified documents and a statutory declaration within 30 days (s 8(1)-(2)) is prescribed for the purposes of subsection 197(1) of the Act. Failure to comply with that prescription would be a failure to satisfy a requirement prescribed under the Act and so will attract whatever enforcement measures the Act provides for non‑compliance with s 197 and associated provisions. The instrument does not itself specify fines, licences revocation, or other sanctions; those measures, if any, are in the Act.
• Timing obligations for scheme confirmation applications: the restriction that an application must not be made earlier than 15 days after giving the approved summary (s 7(1)) is prescribed for the purposes of paragraph 191(2)(e) of the Act. The Court may dispense (s 7(2)). The instrument does not specify remedies for breach of the timing restriction; any consequences arise through the Act and the Court’s discretion under the Act.

No new criminal offences or penalty amounts

• The instrument contains no new penalty provisions, monetary fines, or criminal offences. It is a regulatory instrument that supplies definitions, computational formulas, and timelines linked to the Act. Any sanction for non‑compliance is to be sought or applied under the Act itself, which the instrument cites as its enabling authority (s 3).

Administrative enforcement risk and compliance exposure

• The instrument shifts some practical enforcement exposure onto companies by prescribing strict document content, certification and statutory declaration requirements, and by constraining APRA’s extension discretion to a reason‑based decision within 14 days (s 8). While the instrument does not spell out penalties, the combination of strict procedural rules and the Act’s enforcement architecture means that non‑compliance creates real administrative risk under the Act.

In short, the instrument creates reviewable procedural decisions (APRA refusal), precise duties to submit documents and make declarations, and computational entitlements; enforcement and penalties arise from the Act’s framework rather than from this instrument’s text.

The instrument is tightly cross‑referenced to the Life Insurance Act 1995 and to other statutory instruments. It functions as subordinate legislation that supplies the operational detail the Act requires. The principal interactions are as follows, with citations to the instrument’s own cross‑references.

Primary enabling statute

• Life Insurance Act 1995: the instrument is made under the Act (s 3). Most provisions expressly state they are "for the purposes of" specific subsections or paragraphs of the Act: the minimum term of annuities (s 5) for paragraph 9(1)(d); eligible foreign life insurance company (s 6) for paragraph 16ZD(1)(e); timing for scheme confirmation applications (s 7) for paragraph 191(2)(e); documents to be given to APRA (s 8) for subsection 197(1); interest on overdue premiums (s 9) for subsection 210(3); unclaimed money interest calculations (s 10) for paragraph 216(7A)(a); net claim value calculation (s 11) for subsection 223(2); definitions for Schedule 1 to the Act (s 14); and definitions (ss 15-16).
• The instrument therefore must be read and applied alongside the Act. It does not attempt to replicate or displace the Act’s broader provisions; rather it supplies precise rules the Act directs the Governor‑General to prescribe.

Other regulations and instruments referenced

• Superannuation Industry (Supervision) Regulations 1994: the definition of "allocated annuity policy" in s 4(b) expressly includes contracts that meet subregulation 1.05(4) of the SIS Regulations. The instrument’s operational definition thus imports the SIS Regulations’ technical standards when determining whether a policy is an "allocated annuity policy" for the Act’s purposes.
• Payment Systems and Netting Regulations 2001: s 15 prescribes that, for the purposes of paragraph (b) of the definition of derivative in Schedule 1 to the Act, something is prescribed if any of paragraphs 6(2)(a)-(h) of the Payment Systems and Netting Regulations 2001 apply to an obligation under that thing. The instrument therefore ties the Act’s derivative definition to the Payment Systems regime. The instrument includes the statutory note present in those regulations indicating that paragraphs 6(2)(a)-(h) identify obligations that are not eligible obligations in relation to a close‑out netting contract, and gives examples including contracts of insurance.
• Statutory Declarations Act 1959: s 4 defines "certified copy of a document" as a copy certified in writing by a person prescribed for the purposes of paragraph 8(b) of the Statutory Declarations Act 1959. This imports the Statutory Declarations Act’s certification standard and the identity of authorised certifiers into the operation of s 8 document requirements.

Transitional interaction with prior regulations

• Life Insurance Regulations 1995 and Treasury Laws Amendment (Insurance) Regulations 2024: s 13(1) provides that, despite repeal of regulation 9.04 of the Life Insurance Regulations 1995 by the Treasury Laws Amendment (Insurance) Regulations 2024, that repealed regulation continues to apply, on and after the commencement of s 13, in relation to transfers or amalgamations completed before commencement. Section 13(2) makes clear that s 8 of the new instrument applies to transfers or amalgamations completed on or after commencement. This transitional language allocates pre‑commencement and post‑commencement transfers to different regulatory texts.
• Court processes and the Act: s 7 preserves the Court’s power under subsection 191(5) of the Act to dispense with giving an approved summary to policy holders. The instrument’s timing rule therefore interacts with the Act’s judicial discretion.

Other cross‑statute interactions

• Schedule 1 approved bodies and the Act’s Schedule 1: s 14 declares that for the purposes of the definition of approved body in Schedule 1 to the Act, approved body has the meaning given by Schedule 1 to the instrument. The instrument supplies an extensive list of exchanges and clearing houses, thereby determining which counterparties or market infrastructures qualify as "approved bodies" under the Act’s schedule‑based references.

Operational consequence of these interactions

• Because the instrument ties several Act concepts to external instruments (SIS Regulations, Payment Systems Regulations, Statutory Declarations Act), persons using the instrument will need to consult those instruments to apply the definitions or determine certification standards. The instrument therefore operates as a nexus point between the Act and a small set of other regulatory instruments.

The instrument is short and was made and commenced as a single instrument; the text contains its own commencement and transitional provisions and records the context of a contemporaneous repeal in the older Life Insurance Regulations 1995. Key chronological facts (as set out in the instrument itself) are:

• Making and commencement: The instrument is dated 19 February 2024 (preamble) and the commencement table in regulation 2 states that "the whole of this instrument" commenced on 1 March 2024 (s 2). The table also includes the note that the table relates only to the provisions as originally made and will not be amended to deal with later amendments.
• Transitional application of new provisions: Section 12 states that s 7 (the application timing for confirmation of schemes) applies in relation to an application for confirmation of a scheme made on or after the commencement of that section. That confirms the prospective application of s 7 to scheme confirmation applications filed on or after commencement.
• Transitional interaction with prior regulation 9.04: Section 13 addresses the repeal of regulation 9.04 of the Life Insurance Regulations 1995 by the Treasury Laws Amendment (Insurance) Regulations 2024. It prescribes that the repealed regulation 9.04 continues to apply, on and after the commencement of s 13, in relation to any transfer or amalgamation completed before that commencement (s 13(1)). Section 13(2) makes s 8 applicable to transfers or amalgamations completed on or after commencement. This transitional arrangement allocates compliance obligations between the old and new regulations based on completion date of the transfer/amalgamation.
• Original instrument only: the instrument’s own notes state that the commencement table relates only to the provisions of the instrument "as originally made" and will not be amended in the table to reflect later amendments. The instrument does not record any prior amendments or versions; the schedule "Approved bodies" is appended to the instrument and forms part of its original content.

Because this instrument is the 2024 instrument and contains explicit transitional clauses relevant to transfers/amalgamations straddling its commencement date, the amendment history is limited to those immediate transitional arrangements. No further amendments, repeals or historical versions are recorded within the instrument’s text.

Practitioners should therefore treat this instrument as the operative subordinate legislation from 1 March 2024 for matters within its scope, subject to the transitional carve‑outs in s 13 for transfers/amalgamations completed before its commencement. Any future amendments would appear in a later amending instrument and would require checking the Federal Register of Legislation or Gazette for updates.

The instrument itself does not record any litigation history. It is a regulation that prescribes technical and procedural details under the Life Insurance Act 1995 and does not cite or rely on judicial decisions. The text does, however, engage courts and court processes in defined ways that will be relevant in any litigation arising from scheme confirmations, transfers/amalgamations, or reviewable decisions.

Court‑related provisions in the instrument

• Scheme confirmation and the Court: regulation 7 prescribes a timing constraint for applications under paragraph 191(2)(e) of the Act , an application must not be made earlier than 15 days after the first day on which an approved summary is given to every affected policy holder (s 7(1)). Regulation 7(2) preserves the Court’s power under subsection 191(5) of the Act to dispense with the need to give the approved summary. This interacts directly with Court discretion under the Act and is likely to be relevant in litigation or contested scheme confirmations where the giving of the approved summary is at issue.
• Court order as a document to be provided to APRA: regulation 8(1)(b)(iv) requires a certified copy of the Court order confirming the scheme to be provided to APRA. Any dispute about the validity of the Court order, or the availability of required certified copies, would be litigable under the Act and through ordinary judicial processes.
• APRA reviewable decision: regulation 8(5) prescribes that APRA’s decision to refuse an extension under regulation 8(4)(a)(ii) is a reviewable decision under subsection 236(1) of the Act. That prescription brings decisions by APRA under the supervision and review regime established in the Act, creating a potential pathway to judicial or administrative review where APRA refuses extensions.

No cases named in the instrument

• The instrument does not name or rely upon any precedent cases, nor does it summarise judicial reasoning. There is no statutory history of litigation provided in the instrument itself.

Implication for practitioners

• Litigation concerning the instrument, to the extent it arises, will likely be procedural or administrative: disputes over whether the approved summary was properly given, the adequacy or timeliness of documents provided to APRA, the content of statutory declarations, APRA’s exercise of its extension discretion and review, or the application of the instrument’s computations (for example, the correct calculation of interest on unclaimed money or the proper rounding).
• Because the instrument defers enforcement mechanics to the Act (and imports reviewability of particular APRA refusals), any contested issues will be litigated within the framework set out in the Act and in relevant administrative law, rather than under the instrument’s own separate sanctions.

In short, while this regulation does not record litigation, it specifies points of interaction , Court confirmation of schemes and APRA reviewable decisions , which are natural focal points for future litigation and administrative review under the Act.

The instrument contains several technical details that present practical pitfalls and compliance traps. Below are the most salient, with exact statutory references.

Timing traps

• 15‑day waiting rule for scheme confirmation applications: regulation 7(1) provides that an application under paragraph 191(2)(e) of the Act must not be made earlier than 15 days after the first day on which an approved summary of the scheme has been given to every affected policy holder. The phrase "first day on which an approved summary ... has been given" requires careful operational tracking: if some holders receive the summary later than others, the 15‑day clock starts from the first day any holder received it, potentially allowing early application unless the applicant confirms that every affected holder received the summary no earlier than 15 days before filing. The Court can dispense under subsection 191(5) of the Act (s 7(2)), but relying on judicial dispensation is a procedural risk.
• 30‑day deadline to provide documents to APRA and limited extension: regulation 8(2) requires documents be given to APRA within 30 days after completion. A written application for an extension must be made before the end of the 30 days (s 8(3)). APRA may grant an extension of no longer than 30 days only if it believes it was not reasonably possible to give the documents within 30 days; otherwise APRA must refuse (s 8(4)(a)(i)-(ii)). APRA has 14 days to decide and must notify in writing (s 8(4)(b)). The interplay of these deadlines creates a tight calendar and limited margin for delay.
• Transitional carve‑out: regulation 13(1) keeps the repealed regulation 9.04 of the Life Insurance Regulations 1995 applicable to transfers/amalgamations completed before commencement. Companies with transfers that straddle the commencement date must determine which regime applies based on completion date , a potential trap if completion date is ambiguous.

Rounding and computation quirks

• Overdue premium interest rounding down: regulation 9(3) mandates that, if the mean 10 year Commonwealth Government bond yield (calculated per s 9(2)) is not a multiple of 0.25%, it must be rounded down to the nearest multiple of 0.25%. This rounding down reduces the base yield and therefore the interest rate available to a life company as a lawful charge; companies relying on internal rounding assumptions could undercharge or overcharge if they apply a different rounding convention.
• Bond yield averaging window: the "10 year Commonwealth Government bond yield" is the mean of yields at the end of each of the last six successive half financial years ending before the day (s 9(2)). This half‑financial year averaging (six observations) produces an historical, lagged average that must be sourced from Reserve Bank published figures. Misreading "half financial year" versus calendar half‑year or other averaging conventions would produce incorrect rates.
• Unclaimed money interest computed per financial year: regulation 10(6)-(7) requires the interest for returned unclaimed money to be worked out by adding interest for each financial year that occurs wholly or partly during the "interest period" (s 10(6)). Each year's interest uses a formula involving the "amount" (which accumulates prior interest), "days interest payable" for that financial year and a CPI‑based interest rate for that year (s 10(7)-(9)). This rolling, compounding‑style computation is more complex than a single simple rate for the whole period and requires financial year breaking and CPI quarter indexing discipline. The interest period starts on the later of 1 July 2013 and the day the life company paid the unclaimed money to the Commonwealth (s 10(5)(a)); that lookback to 2013 is an odd but explicit floor.
• Very fine rounding on CPI rate: regulation 10(10) requires the interest rate to be rounded up to the nearest multiple of 0.0001% if not already a multiple of that. That is an extremely fine quantum and will require precise numeric handling to comply.
• Floor at zero: regulation 10(11) requires that any negative calculated interest rate be rounded up to 0%. This means no negative interest is payable to life companies even if CPI declines by the specified formula.

Definition and scope traps

• China definition excludes certain WTO members: regulation 6(2) clarifies that references to China in regulation 6(1)(a) do not include Hong Kong, Macao, or the Separate Customs Territory of Taiwan, Penghu, Kinmen and Matsu. Foreign insurers incorporated or authorised in those territories will not qualify under the China head in regulation 6(1)(a). Practitioners must check incorporation and authorisation against the precise wording.
• Dependence on other instruments: the definition of allocated annuity policy imports subregulation 1.05(4) of the SIS Regulations (s 4). The derivative definition references paragraphs 6(2)(a)-(h) of the Payment Systems and Netting Regulations 2001 (s 15). Compliance demands active cross‑checking of these external instruments; failing to reconcile definitions across instruments is a practical hazard.
• Certified copy certification standard: the instrument defines "certified copy of a document" by reference to persons prescribed under paragraph 8(b) of the Statutory Declarations Act 1959 (s 4). The identity of acceptable certifiers is therefore external to the instrument and practitioners must ensure the certifier used is authorised under that Act.

Approved bodies list

• Schedule 1 is extensive and prescriptive as to which exchanges/clearing houses are "approved bodies" for the purpose of the Act (s 14). Item 167 creates a residual category for a body that performs clearing house functions in relation to an approved body, either under the approved body's rules or under a law , but only in relation to an approved body that does not itself perform clearing (Sch 1, item 167). Misclassifying a counterparty or assuming a non‑listed entity is an approved body without checking item 167 conditions may produce compliance mistakes.

Document content risk

• Statutory declaration content is specific: regulation 8(1)(c) requires the declaration to set out payments made, a reasonable estimate of future payments, and an express statement that, to the declarant’s belief, no other payments have been made or will be made by, or with the knowledge of, a party to the agreement or deed (s 8(1)(c)(i)-(iii)). Failing to include the exact content, or making inaccurate statements in the declaration, could have legal consequences under the Statutory Declarations Act and the Act’s enforcement provisions.

In sum, the main gotchas are tightly calendared procedural deadlines, precise computational and rounding rules, dependence on external instruments for definitional content and certification, and the strict statutory declaration content requirement. Practical compliance requires robust project management, numerical precision and cross‑instrument checking.

This section sets out a practical, source‑grounded checklist and process map for the principal compliance obligations created or clarified by the instrument. Cite the relevant regulation(s) for each action.

1. Implement a calendar and governance matrix for transfers/amalgamations (reg 7 and reg 8)

   • Before making an application under paragraph 191(2)(e) of the Act, confirm the date on which the approved summary was first given to every affected policy holder. Do not file the application earlier than 15 days after that "first day" unless the Court dispenses under subsection 191(5) of the Act (reg 7(1)-(2)).
   • Maintain records proving when the approved summary was given to each affected policy holder in the form required by the Act.
   • If there is any uncertainty about whether the summary was given in accordance with paragraph 191(2)(c) of the Act, consider seeking a Court dispensation prior to filing.

2. Prepare and deliver the APRA document package for completed transfers/amalgamations (reg 8(1)-(2))

   • Assemble the following documents to give APRA within 30 days after the transfer or amalgamation is completed (reg 8(1)-(2)): a) a statement of the nature and terms of the transfer or amalgamation (reg 8(1)(a)); b) certified copies of:
     • the scheme providing for the transfer or amalgamation (reg 8(1)(b)(i));
     • each actuarial report or other report (if any) on which the scheme and the agreement/deed are founded (reg 8(1)(b)(ii));
     • the agreement or deed effecting the transfer/amalgamation (reg 8(1)(b)(iii));
     • the Court order confirming the scheme (reg 8(1)(b)(iv));
     • a statement of assets and liabilities of each company affected by the scheme within the meaning of s 189 of the Act (reg 8(1)(b)(v)). c) a statutory declaration by the principal executive officer of the latter company that:
     • sets out, in relation to the transfer or amalgamation, each payment made (reg 8(1)(c)(i));
     • sets out a reasonable estimate of each payment to be made in the future (reg 8(1)(c)(ii));
     • states that the declarant reasonably believes that no other payment has been made, or will be made, in relation to the transfer or amalgamation by, or with the knowledge of, a party to the agreement or deed (reg 8(1)(c)(iii)).
   • Ensure all copies are "certified copies" as defined in reg 4 (certification under the Statutory Declarations Act 1959, para 8(b)).

3. Manage the 30‑day deadline and use APRA extension process if needed (reg 8(2)-(4))

   • If you cannot meet the 30‑day deadline, apply in writing to APRA for an extension before the end of the 30 days (reg 8(3)).
   • Provide reasons showing it was not reasonably possible to supply the documents within 30 days; APRA may grant an extension of no longer than 30 days if it so believes (reg 8(4)(a)(i)). If APRA refuses, that refusal is a reviewable decision under the Act (reg 8(4)(a)(ii); reg 8(5)).
   • Expect APRA to decide within 14 days and to give written notice (reg 8(4)(b)). Build time for potential review into your operational plan.

4. Ensure correctness of statutory declaration content (reg 8(1)(c))

   • The statutory declaration must be precise as to payments made and reasonable future estimates and must include the declarant’s belief statement about other payments. Verify factual bases and supporting documentation before the declaration is executed to reduce the risk of inaccuracies.

5. Compute permissible overdue premium interest correctly (reg 9)

   • When charging interest on overdue premiums, apply the formula rate = (10 year Commonwealth Government bond yield) + 3 percentage points (reg 9(1)).
   • Calculate the 10 year Commonwealth Government bond yield as the mean of the 10 year bond yields shown in figures published by the Reserve Bank of Australia at the end of each of the last six successive half financial years ending before the day in question (reg 9(2)).
   • If the mean is not a multiple of 0.25%, round it down to the nearest 0.25% and then add 3 percentage points (reg 9(3)). Document the RBA figures used and the rounding steps to support audit trails.

6. Apply the unclaimed money interest method when Commonwealth returns funds (reg 10)

   • Identify the relevant "interest period": starts on the later of 1 July 2013 or the day the life company paid the unclaimed money to the Commonwealth; ends on the 14th day after the Minister causes payment back to the life company (reg 10(5)).
   • If unclaimed money was paid to the Commonwealth in multiple instalments, compute interest separately for each instalment and separately for each return payment by the Commonwealth (reg 10(3)-(4)) , follow the instrument’s example for mechanics.
   • For each financial year occurring wholly or partly within the interest period, compute interest using the formula in reg 10(7): (amount × days interest payable × interest rate for the financial year) ÷ number of days in the financial year. "Amount" includes the unclaimed money plus interest already worked out for earlier financial years (reg 10(7)). Round monetary results down to the nearest whole dollar and cents (reg 10(8)).
   • Compute the interest rate for each financial year using the CPI formula in reg 10(9): percentage change between the latest March CPI quarter and the second latest March CPI quarter published before the start of the financial year. Round up to the nearest 0.0001% if necessary (reg 10(10)); if negative, set the rate to 0% (reg 10(11)).

7. Calculate net claim value per regulation (reg 11)

   • For purposes of subsection 223(2) of the Act, calculate net claim value at